| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/08/2014 | EP2680899A2 Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
| 01/08/2014 | EP2680885A1 Combination vaccines with lower doses of antigen and/or adjuvant |
| 01/08/2014 | EP2680862A1 Encapsulated cells for hormone replacement therapy |
| 01/08/2014 | EP2680860A1 Use of bacterial endotoxins and lipoteichoic acids to improve postpartal health and productivity of dairy cows and their newborns |
| 01/08/2014 | EP2680859A2 Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection |
| 01/08/2014 | EP2680858A1 Proteasome inhibitor delanzomib for use in the treatment of lupus |
| 01/08/2014 | EP2680857A1 Oleyl phosphocholine for the treatment of mycosis |
| 01/08/2014 | EP2680856A1 Use of aldosterone receptor antagonists for treating female sexual dysfunction and migraine |
| 01/08/2014 | EP2680855A1 Steroid tetrol solid state forms-2 |
| 01/08/2014 | EP2680854A1 Method for administration of a gamma secretase inhibitor |
| 01/08/2014 | EP2680853A1 Treatment of cancer with dopamine receptor antagonists |
| 01/08/2014 | EP2680852A1 Pharmaceutically active disubstituted triazine derivatives |
| 01/08/2014 | EP2680851A2 Fused bicyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors |
| 01/08/2014 | EP2680850A2 Alkyne substituted quinazoline compound and methods of use |
| 01/08/2014 | EP2680849A2 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mglur5 negative allosteric modulators and methods of making and using the same |
| 01/08/2014 | EP2680848A1 Stable compositions of tetrahydrobiopterin |
| 01/08/2014 | EP2680847A1 Pyrimidine compounds inhibiting the formation of nitric oxide and prostaglandin e2, method of production thereof and use thereof |
| 01/08/2014 | EP2680846A1 Use of n-(4-methoxyphenyl)-1-phenyl-1h-pyrazol-3-amine and related compounds |
| 01/08/2014 | EP2680845A2 Gene cluster for biosynthesis of cycloclavine |
| 01/08/2014 | EP2680844A2 Amino-quinolines as kinase inhibitors |
| 01/08/2014 | EP2680843A2 Derivatives of pyrazole-substituted amino-heteroaryl compounds |
| 01/08/2014 | EP2680842A1 Methods of treating a disease or condition of the central nervous system |
| 01/08/2014 | EP2680841A1 Use of glycopyrrolate for treating tachycardia |
| 01/08/2014 | EP2680840A1 Novel benzodioxole piperidine compounds |
| 01/08/2014 | EP2680839A1 Co -administration of eribulin and farletuzumab for the treatment of breast cancer |
| 01/08/2014 | EP2680838A1 TREATMENT OF ARTERIAL AGEING BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR |
| 01/08/2014 | EP2680837A2 COMPOSITIONS AND METHODS COMPRISING C16:1n7-PALMITOLEATE |
| 01/08/2014 | EP2680836A2 New compositions for treating neurological disorders |
| 01/08/2014 | EP2680835A2 Treatment of cerebral ischemia |
| 01/08/2014 | EP2680834A1 Semisolid aqueous pharmaceutical composition containing tapentadol |
| 01/08/2014 | EP2680833A1 Parenteral administration of tapentadol |
| 01/08/2014 | EP2680832A1 Aqueous pharmaceutical formulation of tapentadol for oral administration |
| 01/08/2014 | EP2680831A1 Treatment of arterial ageing by raas inhibitor |
| 01/08/2014 | EP2680829A1 Compositions and methods for non-surgical treatment of ptosis |
| 01/08/2014 | EP2680827A1 Particles containing a growth factor, and uses thereof |
| 01/08/2014 | EP2680826A1 Vitamin d composition |
| 01/08/2014 | EP2680825A1 Prucalopride oral solution |
| 01/08/2014 | EP2680823A1 Binder powders |
| 01/08/2014 | EP2680821A2 Liposome formulation comprising an anti-tumour active substance, method for its preparation and pharmaceutical compositions comprising it |
| 01/08/2014 | EP2680819A2 Dodecafluoropentane emulsion as a stroke and ischemia therapy |
| 01/08/2014 | EP2680818A1 Chemical composition with hydrogen peroxide and a nanoemulsion of long-chained alcohols |
| 01/08/2014 | EP2680816A1 Non-aqueous silicone-based ophthalmic formulations |
| 01/08/2014 | EP2680813A1 Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer |
| 01/08/2014 | EP2680697A1 Process for the preparation of an orexin receptor antagonist |
| 01/08/2014 | EP2680695A1 Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| 01/08/2014 | EP2680694A1 Histone deacetylase inhibitors |
| 01/08/2014 | CN103502319A Pharmaceutical composition containing block copolymer comprising boric acid compound |
| 01/08/2014 | CN103502275A Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same |
| 01/08/2014 | CN103502260A Method for producing 2-o-a-d-glucosyl-l-ascorbic acid anhydrous crystal-containing powder |
| 01/08/2014 | CN103502250A Novel antifungal 5,6-dihydro-4h-pyrrolo[1,2-a][1,4]benzo- diazepines and 6H-pyrrolo[1,2-a][1,4]benzodiazepines substituted with heterocyclic derivatives |
| 01/08/2014 | CN103502249A Azaindole derivatives as tyrosine kinase inhibitors |
| 01/08/2014 | CN103502248A Pyrazolo pyrimidine derivatives |
| 01/08/2014 | CN103502247A 7-azaindole derivatives |
| 01/08/2014 | CN103502245A L-proline and citric acid co-crystals of (2s, 3r, 4r, 5s, 6r)-2-(3-((5- (4-fluorophenyl)thiophen-2-yl) methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol |
| 01/08/2014 | CN103502244A Compound for increasing kinase active and application thereof |
| 01/08/2014 | CN103502242A Isoindolinone derivatives |
| 01/08/2014 | CN103502241A Substituted pyrimidinyl-pyrroles active as kinase inhibitors |
| 01/08/2014 | CN103502240A Azole derivative |
| 01/08/2014 | CN103502239A Pyridinyl- and pyrazinyl-methyloxy-aryl derivatives useful as inhibitors of spleen tyrosine kinase (SKY) |
| 01/08/2014 | CN103502237A FAAH inhibitors |
| 01/08/2014 | CN103502236A Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid |
| 01/08/2014 | CN103502234A Method for preparing t-butyl 2-((4R,6S)-6-formyl-2,2-dimethyl-1,3-dioxan-4-yl)acetate |
| 01/08/2014 | CN103502227A 1,3 oxazines as bace1 and/or bace2 inhibitors |
| 01/08/2014 | CN103502226A Cycloalkenyl aryl derivatives for CETP inhibitor |
| 01/08/2014 | CN103502225A Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators |
| 01/08/2014 | CN103502219A Novel small-molecules as therapeutics |
| 01/08/2014 | CN103502217A Diarylacetylene hydrazide containing tyrosine kinase inhibitors |
| 01/08/2014 | CN103502215A Prodrugs of D-gamma-glutamyl-D-tryptophan and D-gamma- glutamyl-L-tryptophan |
| 01/08/2014 | CN103502213A Alkaloid ester and carbamate derivatives and medicinal compositions thereof |
| 01/08/2014 | CN103502203A Methods of making L-ornithine phenyl acetate |
| 01/08/2014 | CN103501820A Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells |
| 01/08/2014 | CN103501813A Tolerogenic synthetic nanocarriers to reduce antibody responses |
| 01/08/2014 | CN103501812A Tolerogenic synthetic nanocarriers for allergy therapy |
| 01/08/2014 | CN103501800A Beautiful-skin-promoting agent and use thereof |
| 01/08/2014 | CN103501794A Brain-targeting functional nucleic acid and use thereof |
| 01/08/2014 | CN103501793A Antisense oligonucleotides |
| 01/08/2014 | CN103501792A Panaxadiol-containing composition |
| 01/08/2014 | CN103501791A Improved suspension formulation of a corticosteroid for administration by inhalation |
| 01/08/2014 | CN103501790A 6-substituted estradiol derivatives for use in remyelination of nerve axons |
| 01/08/2014 | CN103501789A Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6 |
| 01/08/2014 | CN103501788A Pyridopyrazine derivatives and their use |
| 01/08/2014 | CN103501787A Tolerogenic synthetic nanocarriers for generating cd8+regulatory t cells |
| 01/08/2014 | CN103501786A Tolerogenic synthetic nanocarriers |
| 01/08/2014 | CN103501785A Csf-1r inhibitors for treatment of brain tumors |
| 01/08/2014 | CN103501784A Carboxamide compounds and their use as calpain inhibitors v |
| 01/08/2014 | CN103501783A Methods and drug products for treating Alzheimer's disease |
| 01/08/2014 | CN103501782A Pharmaceutical composition for preventing or treating macular degeneration |
| 01/08/2014 | CN103501781A Use of glycopyrrolate for treating tachycardia |
| 01/08/2014 | CN103501780A Novel benzofurane-piperidine compounds |
| 01/08/2014 | CN103501779A Hydrous adhesive patch |
| 01/08/2014 | CN103501778A Pharmaceutical topical composition for use in the treatment and/or in the prevention of infections of skin lesions |
| 01/08/2014 | CN103501777A Pharmaceutically acceptable cocrystals of n-[2-(7-methoxy-1-naphtyl)ethyl]acetamide and methods of their preparation |
| 01/08/2014 | CN103501776A Composition of glycopyrrolate and a beta2-agonist |
| 01/08/2014 | CN103501775A Parenteral administration of tapentadol |
| 01/08/2014 | CN103501774A Semisolid aqueous pharmaceutical composition containing tapentadol |
| 01/08/2014 | CN103501773A Aqueous pharmaceutical formulation of tapentadol for oral administration |
| 01/08/2014 | CN103501772A Composition comprising diindolylmethane and retinoid to treat skin condition |
| 01/08/2014 | CN103501771A Compositions and methods for non-surgical treatment of ptosis |
| 01/08/2014 | CN103501770A Method for producing patch, and patch |
| 01/08/2014 | CN103501765A Topical formulation comprising a corticosteroid as active ingredient |